- Home
- CADL vs SNN Comparison
CADL vs SNN Comparison
Compare CADL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | SNN |
|---|---|---|
| Founded | 1999 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 14.0B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CADL | SNN |
|---|---|---|
| Price | $5.94 | $33.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | $19.43 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 1.0M | 496.7K |
| Earning Date | 11-13-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $5,944,000,000.00 |
| Revenue This Year | N/A | $7.78 |
| Revenue Next Year | N/A | $5.13 |
| P/E Ratio | ★ N/A | $58.80 |
| Revenue Growth | N/A | ★ 5.35 |
| 52 Week Low | $4.25 | $23.69 |
| 52 Week High | $13.68 | $38.79 |
Technical Indicators
Market Signals| Indicator | CADL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 48.25 |
| Support Level | $5.48 | $32.66 |
| Resistance Level | $5.98 | $33.60 |
| Average True Range (ATR) | 0.44 | 0.42 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 63.11 | 51.89 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.